Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel
- 3 February 2011
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 32 (1) , 64-71
Abstract
Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI). Endothelial function improvement has been proposed, among other factors, for this beneficial effect of clopidogrel, but whether this might be associated to its anti-platelet action remains unclear. We tested the hypothesis that clopidogrel improvement of peripheral vascular endothelial function might be associated with inhibition of platelet aggregation. Endothelial function was evaluated before and at least 12 h after 600 mg clopidogrel in 43 SA pts undergoing elective PCI by: (a) reactive hyperemia peripheral arterial tonometry (measuring the Endoscore); (b) circulating endothelial microparticles (EMPs). Response to clopidogrel was measured with point-of-care VerifyNow P2Y12 assay and expressed as platelet reaction unit (PRU) and percent platelet inhibition (%PI). High platelet reactivity after clopidogrel was defined as PRU ≥ 240. Endothelial function improved after clopidogrel in 20 pts. Changes in Endoscore (Δ Endoscore) were significantly correlated with both PRU (r = −0.61, P < 0.001) and %PI (r = 0.57, P < 0.001). Endoscore significantly increased after clopidogrel in pts with PRU < 240 (0.38 ± 0.26 to 0.57 ± 0.33, P < 0.001), but did not in pts with PRU ≥ 240 (0.53 ± 0.31 to 0.40 ± 0.37, P = 0.12). EMPs were also significantly reduced in pts with PRU < 240 (222 [140–593] to 142 [83–371]/μl, P = 0.001), while no changes were observed in pts with PRU ≥ 240 (256 [178–531] to 388 [238–499]/μl, P = 0.55). In patients with stable coronary artery disease, a single 600 mg clopidogrel loading dose improves vascular endothelial function. This improvement is associated with optimal platelet inhibition and it is not observed in patients with post-clopidogrel high platelet reactivity.Keywords
This publication has 36 references indexed in Scilit:
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary InterventionJACC, 2008
- Procoagulant MicroparticlesArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Circulating CD31 + /Annexin V + Apoptotic Microparticles Correlate With Coronary Endothelial Function in Patients With Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Platelets in inflammation and atherogenesisJournal of Clinical Investigation, 2005
- Platelet MicroparticlesArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromesInternational Journal of Cardiology, 2004
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Vitronectin Receptor (α v β 3 ) Mediates Platelet Adhesion to the Luminal Aspect of Endothelial CellsCirculation, 1997